Comparison · NCT02833974-734da27f
GSK2245035 20 ng vs Placebo: Number of Participants Receiving Rescue Medication
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK2245035 20 ng vs Placebo: Number of Participants Receiving Rescue Medication. Trial comparisons, record NCT02833974-734da27f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02833974-734da27f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0253 | 0.278 | wilson | |
| Risk in group 2 | 0.0714 | 0.0127 | 0.315 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0195 | -0.232 | 0.216 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.27 | 0.127 | 12.8 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.107 | 15.8 | log | |
| Number needed to treat, for one more participant with the outcome on GSK2245035 20 ng than on Placebo | 51.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK2245035 20 ng | Participants received 20 ng GSK2245035 intranasal spray solution at the rate of 1 spray per nostril (10 ng per actuation) once weekly for 8 weeks. | 2 | 22 | OG001 |
| Group 2 | Placebo | Participants received placebo matching GSK2245035 intranasal spray solution once weekly for 8 weeks | 1 | 14 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Receiving Rescue Medication
- Description
Salbutamol was administered as rescue medication only to participants who experienced serious discomfort. The data below exclude any Salbutamol administered as part of the planned study procedures (for example the Salbutamol administered after the Bronchial Allergen Challenge \[BAC\] is not counted as a rescue medication).
- Time frame
- Up to Week 20
- Population
- All Subjects Population
Source ClinicalTrials.gov
Trial
- Title
- Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
- NCT number
- NCT02833974
- Phases
- PHASE2
- Conditions
- Asthma
- Interventions
- GSK2245035 Nasal Spray Solution, Placebo Nasal Spray Solution
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-05-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02833974?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02833974-734da27f